©2024 Stanford Medicine
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Not Recruiting
Trial ID: NCT01188486
Purpose
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery.
This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.
Official Title
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Stanford Investigator(s)
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Joseph Shrager
Professor of Cardiothoracic Surgery
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Ann Leung
Professor of Radiology (Thoracic Imaging)
Daniel Sze, MD, PhD
Professor of Radiology (Interventional Radiology)
Nishita Kothary, MD
Professor of Radiology (Interventional Radiology)
Lawrence "Rusty" Hofmann, MD
Professor of Radiology (Interventional Radiology)
Eligibility
INCLUSION CRITERIA
* Either:
* Established primary lung cancer/ cancer metastatic to lung, OR
* Lesion suspicious for malignancy in lung, according to the following criteria:
* Histopathologically confirmed lung cancer or cancer metastatic to lung, OR
* Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR
* Known metastatic cancer, with metastases to the lung based on imaging
* Age \> 18 years old
* Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)
* No prior surgery, chemotherapy, or radiation for the current lung tumor
EXCLUSION CRITERIA
* Prior radiotherapy to thorax
* Iodine allergy
* Contraindication to receiving radiotherapy, unless undergoing surgery
* Pregnant
Intervention(s):
drug: Iohexol
radiation: Computed Tomography (CT)
device: Cyberknife
device: Trilogy
device: True Beam
radiation: Stereotactic Body Radiation Therapy (SBRT)
drug: Iodixanol
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061